Here are the final numbers for IAS 2011
- 7,482 participants, including:
- 5,839 delegates (515 community delegates)
- 1,261 participants from Italy
- 218 scholarship recipients (26 community scholarship recipients)
- 296 media delegates
- 158 volunteers
- 142 countries represented
- 3,552 abstracts submitted
- 50 sessions (23 non-abstract driven sessions, 27 abstract-driven sessions)
- 9 plenary speeches
- 39 exhibits
- 31 satellite meetings
- 6 scientific prizes and awards
- 1,746 Facebook fans, 2,259 #IAS2011 tweets and 38 blog posts
- 20,000+ visits to www.ias2011.org (since Sunday, 17 July)
By Dr. Nora Volkow, Director, National Institute on Drug Abuse, National Institutes of Health
Since the HIV epidemic began, drugs of abuse have played a key role in its expansion, both in the United States and internationally. Worldwide, roughly 16 million people inject drugs, with HIV prevalence rates among injection drug users varying widely by geographic area—from 25% to nearly 90% across particularly hard-hit cities in regions of Eastern Europe and Central Asia, for example. That said, non-injection drug use can also increase the likelihood of HIV transmission through altered judgment and greater risk taking from addiction or drug-induced intoxication. That is why the National Institute on Drug Abuse (NIDA) believes that preventing HIV transmission among drug abusers can have a dramatic impact on improving global health. More...
The silent auction held last night in the Cavea was a great opportunity for delegates to network and have fun in a relaxed atmosphere while bidding for items and consulting time with key experts in the HIV field. Proceeds of the silent auction will be used to contribute to the scholarship programme of the next IAS conference (IAS 2013). A big thank you to all delegates who donated an item and/or attended the silent auction
By Jacques Normand, Director, AIDS Research Program, National Institute on Drug Abuse, National Institutes of Health
Scientific evidence over the last 30 years has shown that a variety of strategies can be effective in reducing HIV transmission among injection drug users. Such strategies include drug treatment programmes, needle exchange programmes (as part of comprehensive HIV prevention), highly active antiretroviral therapy as HIV treatment and prevention, community outreach programs, education, testing and counseling, and sexual risk reduction programs. “Prevention and Treatment of HIV/AIDS among Drug Using Populations: A Global
Perspective,” describes comprehensive HIV prevention. More...
By Mitchell Warren, Executive Director, AVAC
Even amidst the celebratory spirit last year in Vienna with the release of the CAPRISA 004 results, thinking about an end to this epidemic in our lifetimes seemed no more than a pipe dream. But building momentum since last year’s conference, we’ve seen the iPrEx results in November and more recently the landmark data from the HPTN 052 trial announced in May and presented at IAS 2011. And just last week two additional studies – the Partners PrEP and TDF2 studies – provided further data about effectiveness of PrEP.
For the first time in the 30 years of the HIV epidemic, we now have conclusive evidence that earlier treatment initiation in HIV-positive people can also reduce risk of HIV transmission—and that use of ARVs in HIV-negative people can reduce risk of infection. More...
By Professor Michel Kazatchkine, Executive Director, the Global Fund to Fight AIDS, Tuberculosis and Malaria
2011 is a year to reflect upon the remarkable progress we have made in the 10 years since Kofi Annan called for a “war chest” to fight AIDS, a call that was endorsed by the General Assembly soon after and led to the creation of the Global Fund the following year. Even in those exciting and hopeful days, none of us imagined that 10 years later nearly seven million people would be receiving antiretroviral treatment in developing countries and that impressive gains would be achieved in reducing HIV incidence in large parts of the world. More...
The conference is now in full swing and the venue is abuzz with activity and anticipation for the days ahead. Following are some highlights from the Opening Session speeches. The full speeches are available here.
Elly Katabira, International Chair of IAS 2011 and President of the International AIDS Society
“We all know that this event is happening at a scientific watershed in the global AIDS response. Indeed this conference may well turn out to be the marker of that watershed. All the indicators are here: we have a record number of abstract submissions this year, and we are coming off the back-end of two years of significant biomedical advances. More...
By Michel Sidibé, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Under Secretary-General of the United Nations
IAS 2011 offers a wonderful opportunity for the scientific community to share information and give the world the tools to reach our shared vision of Zero New HIV Infections, Zero Discrimination, and Zero AIDS-Related Deaths. These tools are not so far from our reach. Committed scientists, researchers and clinicians are achieving game-changing results that are revolutionizing HIV prevention, as well as HIV care and treatment. The old dichotomies between prevention and treatment no longer exist, as the science to support each is increasingly converging. We can expect further decreases in HIV stigma and discrimination as passionate advocates and activists, and in particular, people living with HIV, raise their voices and take charge of their health. More...
In light of announcements this past week about new data on PrEP effectiveness, one of the conference abstract sessions (MOAX01) was expanded to include presentations on the Partners PrEP Study and the CDC’s TDF2 study, in addition to four originally scheduled presentations on HPTN 052.
HPTN 052, sponsored by the HIV Prevention Trials Network, was the first randomized clinical trial to definitively indicate that an HIV-infected individual can reduce sexual transmission of HIV to an uninfected partner by beginning antiretroviral therapy sooner. The study involved 1,763 HIV-serodiscordant couples at 13 sites across Africa, Asia and the Americas. The trial results were initially released in May 2011 on the recommendation of an independent data and safety monitoring board (DSMB) and Monday’s session will be the first full presentation of the trial data. More...
Two IAS partners, NAM and Clinical Care Options, are providing free scientific coverage of the conference. NAM, the official provider of online scientific reporting, is filing news stories on major scientific presentations and publishing a daily English-language electronic news bulletin that will be translated into French, Portuguese, Spanish and Russian. To receive the bulletin, sign-up here.
Clinical Care Options (CCO), the official online partner for scientific analysis, is providing summaries of key data and analyses by expert faculty during and after the conference. During the conference, CCO’s downloadable audio highlights will provide analyses of studies presented in selected oral sessions. Additional resources such as Expert Analyses and downloadable slides will be available after the conference. The CCO website is a free, international service. One-time free registration is required.